by webmaster | Mar 17, 2025 | Policy & Regulation
I. Introduction The initial approval of a novel medicine in a country or region is usually supported by the same quality, non-clinical and pivotal clinical study datasets used for approval in other jurisdictions (notwithstanding additional clinical studies may be...
by webmaster | Mar 17, 2025 | Policy & Regulation, Uncategorized
Position: Today’s regulatory science supports the development of biosimilars based on analytical (physicochemical and functional) data and a clinical pharmacokinetic study (which includes safety and immunogenicity data) alone. Clinical comparative efficacy studies...